Insider Selling: InfuSystem Holdings, Inc. (NYSE:INFU) CEO Sells 20,000 Shares of Stock

InfuSystem Holdings, Inc. (NYSE:INFU) CEO Richard Dilorio sold 20,000 shares of the stock in a transaction on Monday, November 25th. The shares were sold at an average price of $9.32, for a total value of $186,400.00. Following the completion of the sale, the chief executive officer now owns 436,659 shares in the company, valued at approximately $4,069,661.88. This trade represents a 4.38 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Richard Dilorio also recently made the following trade(s):

• On Wednesday, November 27th, Richard Dilorio sold 5,398 shares of InfuSystem stock. The stock was sold at an average price of $8.87, for a total transaction of $47,880.26.

InfuSystem Stock Performance

NYSE:INFU traded down $0.10 during mid-day trading on Wednesday, reaching $8.85. 39,965 shares of the company’s stock were exchanged, compared to its average volume of 60,063. InfuSystem Holdings, Inc. has a one year low of $5.74 and a one year high of $10.99. The company has a quick ratio of 1.59, a current ratio of 1.98 and a debt-to-equity ratio of 0.50. The business’s fifty day moving average is $7.29. The stock has a market capitalization of $188.15 million, a price-to-earnings ratio of 147.52 and a beta of 1.45.

Analysts Set New Price Targets

Several research analysts have weighed in on the stock. StockNews.com raised shares of InfuSystem from a “buy” rating to a “strong-buy” rating in a report on Friday, November 8th. B. Riley initiated coverage on InfuSystem in a research note on Thursday, September 26th. They set a “buy” rating and a $13.00 target price on the stock.

Hedge Funds Weigh In On InfuSystem

A number of hedge funds have recently added to or reduced their stakes in INFU. Vanguard Group Inc. grew its holdings in shares of InfuSystem by 1.7% during the 1st quarter. Vanguard Group Inc. now owns 1,083,730 shares of the company’s stock valued at $9,288,000 after purchasing an additional 18,432 shares during the last quarter. Sequoia Financial Advisors LLC bought a new position in InfuSystem in the second quarter valued at about $272,000. ARS Investment Partners LLC boosted its stake in shares of InfuSystem by 11.4% during the second quarter. ARS Investment Partners LLC now owns 33,510 shares of the company’s stock valued at $229,000 after purchasing an additional 3,422 shares in the last quarter. Bank of New York Mellon Corp grew its holdings in shares of InfuSystem by 6.1% during the second quarter. Bank of New York Mellon Corp now owns 93,899 shares of the company’s stock worth $641,000 after purchasing an additional 5,391 shares during the last quarter. Finally, Panagora Asset Management Inc. acquired a new position in shares of InfuSystem in the second quarter valued at approximately $208,000. Institutional investors own 71.13% of the company’s stock.

InfuSystem Company Profile

InfuSystem Holdings, Inc, through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada. The company operates in two segments, Patient Services and Device Solutions. It supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states.